363 related articles for article (PubMed ID: 20634495)
1. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study.
Cordonnier C; Rovira M; Maertens J; Olavarria E; Faucher C; Bilger K; Pigneux A; Cornely OA; Ullmann AJ; Bofarull RM; de la Cámara R; Weisser M; Liakopoulou E; Abecasis M; Heussel CP; Pineau M; Ljungman P; Einsele H; ;
Haematologica; 2010 Oct; 95(10):1762-8. PubMed ID: 20634495
[TBL] [Abstract][Full Text] [Related]
2. [Itraconazole for secondary prophylaxis of invasive fungal infection in patients undergoing chemotherapy and stem cell transplantation].
Shi JM; Wang C; Zhou YH; Yu K; Du X; Luo Y; Cai Z; He JS; Ye XJ; Zhang J; Xie WZ; Huang H
Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):413-6. PubMed ID: 23688752
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation.
Marks DI; Pagliuca A; Kibbler CC; Glasmacher A; Heussel CP; Kantecki M; Miller PJ; Ribaud P; Schlamm HT; Solano C; Cook G;
Br J Haematol; 2011 Nov; 155(3):318-27. PubMed ID: 21880032
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation.
Martin T; Sharma M; Damon L; Kaplan L; Guglielmo BJ; Working M; O'Malley R; Hwang J; Linker C
Transpl Infect Dis; 2010 Feb; 12(1):45-50. PubMed ID: 19793068
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Network Meta-analysis.
Wang J; Zhou M; Xu JY; Zhou RF; Chen B; Wan Y
JAMA Netw Open; 2020 Oct; 3(10):e2017652. PubMed ID: 33030550
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
[TBL] [Abstract][Full Text] [Related]
7. Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.
Pepeler MS; Yildiz Ş; Yegin ZA; Özkurt ZN; Tunçcan ÖG; Erbaş G; Köktürk N; Kalkanci A; Yildirim Z
J Infect Dev Ctries; 2018 Sep; 12(9):799-805. PubMed ID: 31999640
[TBL] [Abstract][Full Text] [Related]
8. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.
Winston DJ; Maziarz RT; Chandrasekar PH; Lazarus HM; Goldman M; Blumer JL; Leitz GJ; Territo MC
Ann Intern Med; 2003 May; 138(9):705-13. PubMed ID: 12729424
[TBL] [Abstract][Full Text] [Related]
9. Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study.
Maschmeyer G; Heinz WJ; Hertenstein B; Horst HA; Requadt C; Wagner T; Cornely OA; Löffler J; Ruhnke M;
Eur J Clin Microbiol Infect Dis; 2013 May; 32(5):679-89. PubMed ID: 23271674
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a primary antifungal prophylaxis protocol for preventing invasive mold infections after allogeneic hematopoietic stem cell transplantation.
Herity LB; Cruz OA; Aziz MT
J Oncol Pharm Pract; 2022 Jun; 28(4):794-804. PubMed ID: 33906508
[TBL] [Abstract][Full Text] [Related]
11. An open-label trial of the prophylactic administration of voriconazole in patients who undergo allogeneic hematopoietic stem cell transplantation: study protocol.
Kunitomi A; Hasegawa Y; Hashimoto H; Saito AM; Iida H
Nagoya J Med Sci; 2018 Nov; 80(4):591-595. PubMed ID: 30587873
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.
Park S; Kim K; Jang JH; Kim SJ; Kim WS; Chung DR; Kang CI; Peck KR; Jung CW
J Infect; 2016 Nov; 73(5):496-505. PubMed ID: 27394404
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Trial of Caspofungin vs Triazoles Prophylaxis for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplant.
Dvorak CC; Fisher BT; Esbenshade AJ; Nieder ML; Alexander S; Steinbach WJ; Dang H; Villaluna D; Chen L; Skeens M; Zaoutis TE; Sung L
J Pediatric Infect Dis Soc; 2021 Apr; 10(4):417-425. PubMed ID: 33136159
[TBL] [Abstract][Full Text] [Related]
14. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole.
Trifilio S; Singhal S; Williams S; Frankfurt O; Gordon L; Evens A; Winter J; Tallman M; Pi J; Mehta J
Bone Marrow Transplant; 2007 Sep; 40(5):451-6. PubMed ID: 17589527
[TBL] [Abstract][Full Text] [Related]
15. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.
Walsh TJ; Lutsar I; Driscoll T; Dupont B; Roden M; Ghahramani P; Hodges M; Groll AH; Perfect JR
Pediatr Infect Dis J; 2002 Mar; 21(3):240-8. PubMed ID: 12005089
[TBL] [Abstract][Full Text] [Related]
16. Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis.
Montesinos P; Rodríguez-Veiga R; Boluda B; Martínez-Cuadrón D; Cano I; Lancharro A; Sanz J; Arilla MJ; López-Chuliá F; Navarro I; Lorenzo I; Salavert M; Pemán J; Calvillo P; Martínez J; Carpio N; Jarque I; Sanz GF; Sanz MA
Bone Marrow Transplant; 2015 Nov; 50(11):1465-72. PubMed ID: 26281032
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
[TBL] [Abstract][Full Text] [Related]
18. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
Ziakas PD; Kourbeti IS; Mylonakis E
Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
[TBL] [Abstract][Full Text] [Related]
19. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants.
Mauskopf J; Chirila C; Graham J; Gersten ID; Leather H; Maziarz RT; Baden LR; Bolaños-Meade J; Brown JM; Walsh TJ; Horowitz MH; Kurtzberg J; Marr KA; Wingard JR
Am J Health Syst Pharm; 2013 Sep; 70(17):1518-27. PubMed ID: 23943184
[TBL] [Abstract][Full Text] [Related]
20. Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation.
Rosillo C; Avila AM; Huang YT; Devlin S; Cho C; Montoro J; Maloy MA; Papanicolaou GA; Barba P; Perales MA
Transpl Infect Dis; 2018 Aug; 20(4):e12897. PubMed ID: 29668073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
